FibroBiologics, Inc. (FBLG)

Kritische 8-K Meldungen

WARNUNG: Kritische 8-K-Meldung(en)
HOCH Abgang Schlüsselpersonen (06.03.2026)

Datum	Meldung	Schwere	Filing	Auszug
06.03.2026	Item 5.02 — Abgang Schlüsselpersonen	HOCH	SEC	13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment
05.05.2025	Item 5.02 — Abgang Schlüsselpersonen	HOCH	SEC	Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;
24.01.2025	Item 5.02 — Abgang Schlüsselpersonen	HOCH	SEC	Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;
29.10.2024	Item 5.02 — Abgang Schlüsselpersonen	HOCH	SEC	Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;

Stammdaten

FibroBiologics, Inc., a clinical-stage cell therapy company, develops and commercializes fibroblast-based therapies in the United States. It is developing CybroCell, for the treatment of degenerative disc disease; CYMS101 to treat multiple sclerosis; and CYWC628 for wound healing. The company is also on the early-stage research of CYTER915, which is designed to regenerate or reinvigorate production of the thymus and/or spleen; CYPS317, for the treatment of psoriasis; and TCB190 to treat certain cancers. FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.

Unternehmen & Branche

Name	FibroBiologics, Inc.
Ticker	FBLG
CIK	0001958777
Boerse	US
Sektor	Healthcare
Industrie	Biotechnology
SIC	2834 · Pharmaceutical Preparations

Wertpapier & Kennzahlen

CUSIP	–
ISIN	–
Typ	Common Stock
Marktkapitalisierung	2,8 Mio. USD
Beta	1,11
Dividendenrendite	0,00 %

Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »

Finanzkennzahlen (SEC XBRL)

Periode	Filing	Nettoergebnis	EPS	Aktiva	Eigenkapital
2025-12-31	10-K	-18,646,000	-0.42	9,619,000	6,156,000
2025-09-30	10-Q	-5,778,000	-0.13	8,744,000	125,000
2025-06-30	10-Q	-4,658,000	-0.12	13,907,000	860,000
2025-03-31	10-Q	-4,966,000	-0.14	11,426,000	2,350,000
2024-12-31	10-K	-11,161,000	-0.34	16,445,000	2,735,000
2024-09-30	10-Q	-500,000	-0.01	10,469,000	2,737,000
2024-06-30	10-Q	898,000	0.03	8,912,000	-2,387,000
2024-03-31	10-Q	-8,460,000	-0.27	11,399,000	-3,863,000
2023-12-31	10-K	-16,485,000	-0.68	11,821,000	1,253,000
2023-09-30	10-Q	-2,193,000	-0.08		10,538,000
2023-06-30	10-Q	-2,160,000	-0.08		11,353,000
2023-03-31	10-Q	-2,415,000	-0.18		639,000
2022-12-31	10-K	-5,121,000	-0.18	4,824,000	-3,996,000

Fondsaktivität (Vorquartalsvergleich)

Keine Fondsdaten für dieses Unternehmen vorhanden.

Insider-Transaktionen (12 Monate)

Datum	Insider	Rolle	Typ	Stückzahl	Kurs	Wert (USD)	Δ
2026-03-04	Khoja Hamid	Officer, Chief Scientific Officer	Open Market Purchase	30,000	0.38	11,400.00	+66,4%
2026-03-04	O'HEERON PETE	Director, Officer, CHIEF EXECUTIVE OFFICER	Open Market Purchase	15,872	0.38	6,005.96	+35,0%
2026-03-03	O'HEERON PETE	Director, Officer, CHIEF EXECUTIVE OFFICER	Open Market Purchase	18,200	0.41	7,372.82	+42,9%
2026-03-02	O'HEERON PETE	Director, Officer, CHIEF EXECUTIVE OFFICER	Open Market Purchase	17,428	0.35	6,152.08	+35,8%
2026-03-02	Davis Jason	Officer, Chief Financial Officer	Open Market Purchase	70,000	0.41	28,973.00	+168,7%
2026-02-27	GARCIA RUBEN A	Officer, General Counsel	Open Market Purchase	40,000	0.33	13,056.00	+76,0%
2025-12-11	GARCIA RUBEN A	Officer, General Counsel	Open Market Purchase	140,000	0.34	47,600.00	+277,2%
2025-05-27	Khoja Hamid	Officer, Chief Scientific Officer	Open Market Purchase	20,000	0.84	16,800.00	+97,8%

Top-Fondshalter

Keine Fondsdaten zu dieser Aktie vorhanden.